Home Tags Acorda Therapeutics

Tag: Acorda Therapeutics

Acorda Therapeutics of Ardsley to cut staff by 15% and make...

Acorda Therapeutics is cutting its workforce by 15% and outsourcing certain unspecified operations, resulting in a savings of $20 million, according to the Ardsley-based...

Westchester IDA approves tax exemption for BioMed Realty’s Ardsley Park $38M...

The Westchester County Industrial Development Agency has given final approval of a $905,373 sales tax exemption for a $38 million renovation project at BioMed...

Acorda patents ruled invalid for MS drug Ampyra

The Ardsley biotech company faces competition from generic manufacturers after a judge ruled four of five patents invalid for Acorda's top-selling drug brand Ampyra.

Acorda drug for Parkinson’s shows positive trial results

The Ardsley biotech company's inhalable form of L-dopa improved motor function in patients with re-emergent symptoms of Parkinson's Disease.

Acorda gets $1.4M to develop respiratory treatment

The Bill & Melinda Gates Foundation gives Acorda Therapeutics a $1.4 million grant to develop an inhaled treatment for infant respiratory distress syndrome.

Acorda CEO named chairman of biotech trade association

Ron Cohen, president and CEO of Ardsley-based Acorda Therapeutics, is elected chairman of the board for the Biotechnology Industry Organization.

Acorda named among best places to work in New York

Based on a survey, Best Companies Group names Ardsley-based Acorda Therapeutics one of the best companies to work for in New York.

Acorda partnership yields exhibit on ‘evolution of beauty’

The Raw Beauty Project NYC photo exhibit at Acorda Therapeutics provides glimpses into the lives of women with spinal cord injuries.

Acorda earnings beat Wall Street expectations

Acorda Therapeutics Inc. beats Wall Street expectations on earnings per share and revenue for the fourth quarter.

Investing in Westchester’s biotech surge

Companies like Regeneron and Acorda – and their investors – hope to make a profit, but how does an investor get in on Westchester County’s biotech boom?

Westchester biotech companies report strong quarters

Acorda Therapeutics posts earnings well above Wall Street expectations, while Regeneron and Progenics also post a profit.

Acorda completes $525M deal to acquire Civitas

The purchase of the Boston-area company gives Acorda global rights to a promising drug treatment for Parkinson's disease.

Acorda to pay $525M for Boston biopharmaceutical company

Acorda Therapeutics Inc. in Ardsley expects to close in the fourth quarter on its cash acquisition of Civitas Therapeutics.

Three Westchester biotech companies announce Q2 earnings

Regeneron Pharmaceuticals and Acorda Therapeutics post gains in earnings compared to the second quarter last year, while Progenics Pharmaceuticals sees a loss.

Acorda files patent infringement suit over MS drug Ampyra

The Ardsley company alleges that Mylan Inc.'s application to get a generic form of the drug approved constitutes infringement of Acorda's patents.